| 988P Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP) SS Ramalingam, C Zhou, TM Kim, JCH Yang, GJ Riely, T Mekhail, ... Annals of Oncology 33, S1004, 2022 | 10 | 2022 |
| Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung … JCH Yang, C Zhou, PA Jänne, SS Ramalingam, TM Kim, GJ Riely, ... Expert Review of Anticancer Therapy 23 (1), 95-106, 2023 | 2 | 2023 |
| Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study S Popat, S Ramalingam, C Zhou, T Kim, J Yang, G Riely, T Mekhail, ... Lung Cancer 178, S35, 2023 | | 2023 |
| Mobocertinib (TAK-788) in metastatic EGFR Exon 20 Insertions (ex20ins)+ NSCLC: Results of platinum-experienced Patients and the EXCLAIM Cohort of a Phase 1/2 Study D Misch, S Ramalingam, C Zhou, TM Kim, JC Yang, G Riely, T Mekhail, ... ONCOLOGY RESEARCH AND TREATMENT 45 (SUPPL 2), 96-97, 2022 | | 2022 |
